EUVIMEDEUVIMED entdecken
VergleichsstudieÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)

Koichi Yamamoto iD, Daisuke Yarimizu iD, Ayano Shimanishi iD, Shunsuke Eguchi iD, Kazuma Iekushi iD, Yoichi Takami iD, Yoichi Nozato iD, Kazuomi Kario iD, Hiromi Rakugi iD

The Journal of Clinical Hypertension · 2025

DOI: 10.1111/jch.14938 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Koichi Yamamoto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Aminobutyrates, Amlodipine, Amlodipine, Valsartan Drug Combination, Antihypertensive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sacubitril/valsartan, an angiotensin receptor‐neprilysin inhibitor, has demonstrated a superior blood pressure‐lowering effect compared with renin‐angiotensin system inhibitors in several clinical trials. However, there has been no available evidence on the comparison between sacubitril/valsartan and calcium channel blockers (CCBs), a well‐established class of antihypertensive drugs. In this open‐label, multicenter study, we aimed to demonstrate the efficacy and safety of sacubitril/valsartan versus amlodipine, one of the most widely used CCBs, after 8 weeks of treatment. A total of 359 Japanese patients with essential hypertension (office systolic blood pressure [SBP] ≥ 150 to < 180 mmHg), aged 18–79, were randomly assigned to receive either once‐daily sacubitril/valsartan 200 mg or once‐daily amlodipine 5 mg in a 1:1 allocation ratio. The primary endpoint was the noninferiority of sacubitril/valsartan compared with amlodipine in mean change in 24‐h SBP from baseline to Week 8, followed by a significance test as a secondary endpoint analysis. The mean change in 24‐h SBP in sacubitril/valsartan was noninferior to that in amlodipine (between‐treatment difference −0.62 mmHg [95% confidential interval: −3.23 to 1.98; p = 0.003 for noninferiority; independent t ‐test with noninferiority margin 3.0 mmHg]), with no significant difference observed ( p = 0.637). There was no significant difference in the incidence of adverse events (AEs). These results suggested that the blood pressure‐lowering effect of sacubitril/valsartan is comparable to that of amlodipine, with no marked differences in tolerability between the two groups. Sacubitril/valsartan, a potent antihypertensive drug comparable to amlodipine, is expected to improve blood pressure control in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminobutyratesAmlodipineAmlodipine, Valsartan Drug CombinationAntihypertensive AgentsEssential HypertensionTetrazolesAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAngiotensin Receptor AntagonistsBiphenyl CompoundsBlood PressureCalcium Channel BlockersDrug CombinationsHypertensionJapanTreatment OutcomeValsartanEast Asian People

Stichwörter der Autor:innen

ambulatory blood pressure monitoringangiotensin receptor‐neprilysin inhibitorcalcium channel blockeressential hypertensionsacubitril/valsartan

Substanzen

AminobutyratesAmlodipineAmlodipine, Valsartan Drug CombinationAngiotensin Receptor AntagonistsAntihypertensive AgentsBiphenyl CompoundsCalcium Channel BlockersDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazoles

Autor:innen und Institutionen

  • Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
  • Medical Affairs, Novartis Pharma K.K., Tokyo, Japan.
  • Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Osaka Rosai Hospital, Osaka, Japan.

ORCID-Profile: Koichi Yamamoto, Daisuke Yarimizu, Ayano Shimanishi, Shunsuke Eguchi, Kazuma Iekushi, Yoichi Takami, Yoichi Nozato, Kazuomi Kario, Hiromi Rakugi

Förderung

  • Novartis Pharma K.K.

Zitieren

APA

Yamamoto, K., Yarimizu, D., Shimanishi, A., Eguchi, S., Iekushi, K., Takami, Y., Nozato, Y., Kario, K., & Rakugi, H. (2025). Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study). The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14938

Vancouver

Yamamoto K, Yarimizu D, Shimanishi A, Eguchi S, Iekushi K, Takami Y, et al. Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study). The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.14938

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Koichi and Yarimizu, Daisuke and Shimanishi, Ayano and Eguchi, Shunsuke and Iekushi, Kazuma and Takami, Yoichi and Nozato, Yoichi and Kario, Kazuomi and Rakugi, Hiromi},
  title = {Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)},
  journal = {The Journal of Clinical Hypertension},
  year = {2025},
  doi = {10.1111/jch.14938}
}
Kostenlos starten →